Carbogen and nicotinamide in the treatment of bladder cancer with radical radiotherapy.

Carbogen and nicotinamide have been evaluated in a phase II study as hypoxia-modifying agents during radical radiotherapy for bladder cancer using a standard daily 20-fraction schedule. Three groups of patients have received (a) nicotinamide alone, given orally in a dose of 80 mg kg(-1) daily with 5...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Hoskin, P. J., Saunders, M. I., Phillips, H., Cladd, H., Powell, M. E., Goodchild, K., Stratford, M. R., Rojas, A.
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group 1997
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2223941/
https://ncbi.nlm.nih.gov/pubmed/9231929
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky